Feldan Therapeutics, a Quebec City, Canada-based biopharmaceutical company that specializes in the development of treatments based on intracellular delivery of therapeutics, raised $16.5M in Series B funding.
Backers included Investissement Québec, Amgen Ventures (United States), GC Cell (South Korea) and FSIT2, as well as existing investors GC Holdings (South Korea) and others.
The company intends to use the funds to conduct clinical phases I/II for Feldan’s FLD-103, an intralesional treatment against basal cell carcinoma (BCC), and to advance its pulmonary program to the preclinical stage.
Led by CEO Francois-Thomas Michaud, Feldan is a biopharmaceutical company focused on the development of treatments based on the intracellular delivery of therapeutics. It has designed the Feldan Shuttle, a proprietary, peptide-based technology that enables the delivery of various compounds inside cells that unlocks the development of therapies by giving access to intracellular targets beyond the reach of existing drugs. Its pipeline focuses on diseases affecting skin and lungs.
FinSMEs
13/06/2023